KarXT xanomeline trospium Cobenfy
Selected indexed studies
- Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management. (Cureus, 2024) [PMID:39525169]
- Xanomeline-trospium (Cobenfy(TM)) for Schizophrenia: A Review of the Literature. (Clin Psychopharmacol Neurosci, 2025) [PMID:39820108]
- Xanomeline/Trospium Chloride: First Approval. (Drugs, 2025) [PMID:39715912]
_Worker-drafted node — pending editorial review._
Connections
KarXT xanomeline trospium Cobenfy is a side effect of
Sources
- Xanomeline/Trospium Chloride: First Approval. (2025) pubmed
- Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management. (2024) pubmed
- Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia. (2025) pubmed
- Xanomeline-trospium (Cobenfy(TM)) for Schizophrenia: A Review of the Literature. (2025) pubmed
- Cobenfy (xanomeline-trospium). (2025) pubmed
- Efficacy and Safety of KarXT (Xanomeline-Trospium; Cobenfy™) in Schizophrenia: A Systematic and Meta-Analysis Review of Randomized Controlled Trials. (2025) pubmed
- Xanomeline/Trospium (Cobenfy) for schizophrenia. (2024) pubmed
- Xanomeline/Trospium (Cobenfy): A Novel Approach for the Treatment of Schizophrenia in Adults. (2025) pubmed
- Cobenfy (xanomeline-trospium): a breakthrough FDA-approved therapy redefining schizophrenia treatment. (2025) pubmed
- Xanomeline. (2006) pubmed